Breast cancer was the first solid tumour for which targeted treatments were available. Endocrine therapy-targeting the oestrogen receptor-was described more than 100 years ago and, as biological knowledge has grown, major advances in treatment and prevention of breast cancer have been made. ...
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 2008;13:373-81.Petrelli F, Cabiddu M, Cazzaniga ME et al. Targeted therapies for the treat- ment of breast cancer in the post-trastuzumab era. The Oncologist 2008; 13:373-381....
Targeted therapies are available for the treatment of estrogen receptor-positive breast cancers,HER2-positive breast cancers, andtriple-negative breast cancer.1 These drugs can work very well, but like the other medications used to treat metastatic breast cancer, resistance usually develops over time. ...
The first occurred during the mid to late 1980’s when hormonal therapy was introduced as a treatment for ER/PR positive breast cancer. The second occurred in the late 1990’s when trastuzumab was introduced in treating HER2 positive breast cancer. These remarkable accomplishments in developing ...
Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer: first planned interim efficacy analysis (abstract 1), 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. 2005. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, ...
Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer: first planned interim efficacy analysis (abstract 1), 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. 2005. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, ...
The FDA has approved SG for the treatment of TNBC and HR+/HER2-breast cancer patients. There are several Trop2-targeted ADCs undergoing clinical trials right now, such as SG, datopotamab deruxtecan, SKB-264, JS-108, ESG-401, and FDA018. Still in the preclinical or discovery stages ...
"Due to the lack of a targeted therapy option, TNBC patients often face a poorer prognosis compared with patients of other types of breastcancer," said BIOE Professor Xiaoming (Shawn) He, corresponding author of the paper. "While we have seen dramatic advancements in breast cancer treatment in...
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low breast cancer.
Endocrine therapy for breast cancer is arguably the first effective systemic treatment for human cancer and is the first targeted therapy [ 1 ]. Similar to many recently developed targeted therapies for breast and other malignancies, hormonal treatments for breast cancer include ligand deprivation (oest...